GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Climb Bio Inc (NAS:CLYM) » Definitions » COGS-to-Revenue

CLYM (Climb Bio) COGS-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Climb Bio COGS-to-Revenue?

Climb Bio's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

Climb Bio's COGS to Revenue for the three months ended in Sep. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Climb Bio's Gross Margin % for the three months ended in Sep. 2024 was N/A%.

Climb Bio COGS-to-Revenue Historical Data

The historical data trend for Climb Bio's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Climb Bio COGS-to-Revenue Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
- - - - -

Climb Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Climb Bio COGS-to-Revenue Calculation

Climb Bio's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Climb Bio's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio  (NAS:CLYM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Climb Bio's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Climb Bio COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Climb Bio's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Climb Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Climb Bio Inc (NAS:CLYM) » Definitions » COGS-to-Revenue
Comparable Companies
CYDY MGX TELO BMEA XFOR RENB FBRX PLX ALGS PVLA VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
2801 Centerville Road, 1st Floor, PMB No.117, Wilmington, DE, USA, 19808-1609
Website
https://www.climbbio.com
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Executives
Emily Pimblett officer: Chief Accounting Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Valerie Morisset officer: Chief Scientific Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ai Eti Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Andrew David Levin director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher officer: EVP and General Counsel 11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle officer: COO & CFO C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe director C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby director, officer: Chief Executive Officer 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109